China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot firm Hinova Pharmaceuticals Inc. (SHA: 688302) to jointly explore and develop overseas markets for their collaborative products.
Collaboration Details
The partnership between Kexing Biopharm and Hinova Pharmaceuticals is designed to leverage their combined strengths in oncology and metabolic diseases. Hinova brings to the table its advanced technology platforms, including PROTAC, deuterium-based drug development, targeted drug discovery, and validation and translational medicine technologies. These platforms support the development of nine product pipelines with global competitive potential.
Key Products and Technologies
Hinova’s pipeline includes deutenzalutamide, an androgen receptor (AR) antagonist currently under development for metastatic castrate-resistant prostate cancer (mCRPC). The company awaits regulatory decisions in China for this promising candidate.
Kexing Biopharm, on the other hand, specializes in the research and development of modified and innovative drugs across various therapeutic areas, including antiviral, anti-tumor, and autoimmune fields. The company boasts a global marketing network covering over 70 countries and regions, positioning it well to support the commercialization of collaborative products.
Strategic Vision
This alliance represents a significant step for both companies in their quest to expand into international markets. By combining Kexing’s global reach with Hinova’s innovative technology platforms, the partnership aims to accelerate the development and commercialization of novel therapies, addressing unmet medical needs worldwide.-Fineline Info & Tech
Leave a Reply